Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Carbon Monoxide for ARDS
NCT03799874Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2019
- Primary completion
- Apr 2021
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Carbon monoxide in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoints: Number of Pre-specified Administration-related Adverse Events at 7 days and Change in Mitochondrial DNA Level at 5 days. Started Sep 2019; status: completed.
02
Drugs
Carbon monoxide
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT03799874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799874.